P1521LRG-1 LEVEL PREDICTS 5-YEAR MORTALITY IN ESRD

Abstract Background and Aims Plasma Leucine-Rich alph-2-Glycoprotein 1(LRG1) is an new biomarker for inflammatory and angiogenetic diseases. whether levels of plasma LRG1 correlate with the co-morbidities of End stage renal disease (ESRD) patients is unknown. Method Plasma LRG-1 and high-sensitivity C-reactive protein were analyzed by ELISA in samples from 169 hemodialysis patients from the Immunity in ESRD study (iESRD study). Baseline co-morbidities were recorded through chart review of medical history. Results High level of LRG 1 showed high mortality in the ESRD. In multivariate-adjusted logistic regression models, higher LRG1 was significantly associated with 5 year mortality after adjusting for gender, hemoglobin, diabetes, hypertension, and level of C-reactive protein. Conclusion LRG1 is a possible poor prognosis marker in ESRD. Higher LRG-1 showed high prevalent CAD and PAOD in our study before. The role of LRG1 and the associated cardiovascular diseases should be analyzed the mechanism in this patient population.

Download Full-text

Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis

Journal of Clinical Lipidology ◽

10.1016/j.jacl.2007.12.003 ◽

2008 ◽

Vol 2 (1) ◽

pp. 43-50 ◽

Cited By ~ 8

Author(s):

Hanaâ Lahrach ◽

Noreddine Ghalim ◽

Hassan Taki ◽

Anass Kettani ◽

Loubna Er-Rachdi ◽

...

Keyword(s):

Renal Disease ◽

End Stage Renal Disease ◽

High Sensitivity ◽

C Reactive Protein ◽

Paraoxonase Activity ◽

Reactive Protein ◽

Stage Renal Disease ◽

End Stage ◽

Serum Paraoxonase

Download Full-text

Multi-Biomarker Risk Stratification of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-Cause Death

Clinical Chemistry ◽

10.1373/clinchem.2004.035741 ◽

2004 ◽

Vol 50 (12) ◽

pp. 2279-2285 ◽

Cited By ~ 145

Author(s):

Fred S Apple ◽

MaryAnn M Murakami ◽

Lesly A Pearce ◽

Charles A Herzog

Keyword(s):

End Stage Renal Disease ◽

Cardiac Troponin ◽

Troponin T ◽

High Sensitivity ◽

C Reactive Protein ◽

Reactive Protein ◽

Multiple Biomarkers ◽

Stage Renal Disease ◽

End Stage ◽

Esrd Patients

Abstract Background: In patients with end-stage renal disease (ESRD), the ability of single and multiple biomarker monitoring to predict adverse outcomes has not been well established. This study determined the prognostic value of multiple biomarkers for all-cause death over 2 years in 399 ESRD patients. Methods: The risk of all-cause death was determined by use of multiple biomarkers based on concentrations for a reference population (normal) and cutoffs based on tertile distributions in the ESRD group. Biomarkers studied included N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP; Dade Behring and Roche assays), and cardiac troponin T (cTnT; Roche) and I (cTnI; Dade Behring and Beckman Coulter assays). Relative risks of death were estimated and survival curves computed. Results: A total of 101 deaths occurred during 594 patient-years of follow-up. Increased NT-proBNP concentrations were not predictive of death on the basis of the normal cutoffs. However, tertile analysis of NT-proBNP was significantly predictive of death and had a ROC area under the curve equivalent to or better than any of the other biomarkers. Biomarkers independently predictive of survival were hsCRP (P <0.001, either assay), cTnT (P <0.05), and cTnI (Dade, P <0.05). Two-year mortality rates were 6% (n = 45) with normal hsCRP, cTnI, and cTnT concentrations; 19% (n = 173) with increased hsCRP or cTnT and normal cTnI; 44% (n = 160) with both hsCRP and cTnT increased and normal cTnI; 61% (n = 21) with increased cTnI (Dade) or 47% (n = 74) with increased cTnI (Beckman) regardless of hsCRP or cTnT concentrations. Defined by the normal cutoffs, increased concentrations of biomarkers were present in various proportions of the 399 patients with ESRD: NT-proBNP, 99%; hsCRP, 46% (both Roche and Dade assays); cTnT, 85%; cTnI, 19% (Beckman assay) and 5% (Dade assay). Conclusions: Although mechanisms likely vary for causation, increased plasma hsCRP, cTnT, and cTnI above the cutoffs for our reference (normal) population were all independently predictive of subsequent death in ESRD patients. Tertile analysis for NT-proBNP also demonstrated prognostic value.

Download Full-text